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Objective. The aim of this paper is to describe a fatal case of hemophagocytic lymphohistiocytosis (HLH) in a patient with
severe heart failure, who was treated with low-dose propranolol. Patient and Interventions. We report on a 7-month-old boy with
Downs syndrome who was born with an unbalanced, left dominant atrioventricular septal defect and aortic coarctation. Despite
coarctation repair and pulmonary artery banding he developed intractable heart failure and fever of unknown origin. Since he
remained in heart failure he received a trial of low-dose propranolol to stabilize his cardiopulmonary status, which resulted in
unexpected immunomodulatory eﬀects. Measurements and Main Result. Immunoactivation was evidenced by high concentrations
of procalcitonin, soluble CD 25, tumor necrosis factor α, and interleukin 6 and 8. Propranolol resulting in hepatic compromise
as indicated by high lactate dehydrogenase and alanine aminotransferase levels. A therapeutic switch from propranolol to the
β1-receptor blocker metoprolol appeared to be instrumental in hemodynamic improvement and allowed discharge from hospital.
However,theinfantultimatelydiedfromsecondaryinﬂammatoryreactivationandintractablepulmonaryobstructivedisease.The
autopsy results revealed HLH. Conclusion. Our case describes HLH secondary to heart failure and Downs syndrome. In this highly
activated inﬂammatory state the beneﬁcial hemodynamic eﬀects of propranolol may be accompanied by immunomodulatory
eﬀects and the risk of acute liver failure. HLH occurs with a distinct pathophysiology, and speciﬁc treatment might be mandatory
to increase the chance of survival.
1.Introduction
HLH is a life-threatening condition which may be diﬃcult to
distinguish from severe sepsis [1]. We report an infant who
presented with a complex congenital heart defect, Downs
syndrome, and fever of unknown origin who appeared to be
in intractable heart failure but the autopsy results revealed
HLH. While in apparent intractable heart failure by clinical
signs, the infant received a trial of low-dose propranolol,
which resulted in immunomodulatory eﬀects characterized
by septic fever, elevated laboratory parameters (Table 1), and
multiorgan dysfunction. The eﬀects of this non selective β-
blocker on a highly activated inﬂammatory state provide
us with an opportunity to gain pathophysiological insights
into interactions between the adrenergic system and the
inﬂammatory response.
2.CaseReport
Wereport ona7-month-old boy withDowns syndromewho
was born with an unbalanced left dominant atrioventricular
septal defect and aortic coarctation. Initially he underwent
aortic coarctation repair. However, despite good restitution
of the systemic obstruction he could not be weaned from
mechanical ventilation and subsequently underwent pul-
monary arterial banding, which reduced pulmonary arterial
pressure to 50% of systemic pressure and the pulmonary-to-
systemic ﬂow ratio to 1.5:1. Also a plication operation was2 Cardiology Research and Practice
Table 1
Parameter Normal Value Baseline SIRS I SIRS II Discharge SIRS III
Timeframe (days) 3 4 2 18
Age (weeks) 23 24 27 29
Cardiovascular changes
Heart rate (1/min) 130 110 100 100 150
Fractional shortening (%) 45 45 32 59 36
LV Pressure (mmHg)§ 101 79 79 71 63
Mean arterial pressure (mmHg) 86 65 74 60 50
Pulmonary artery pressuresys (mmHg)# 63 61 48 30 40
Hepatic changes
GOTmax (U/l) 0–35 319 28839 3778 107 323
LDHmax (E/l) 0–250 220000 9097 530 2753
Bilirubinmax (mmol/l) 0.4–1.2 2.8 9.51 6.16 7.06
Renal changes
Creatininemax (mg/dl) 0.70–1.20 0.45 0.62 1.94 0.67 1.57
Ureamax (mg/dl) 11–55 75 133 122 210
Coagulation
Thrombocytemin (1000/l) 140000–400000 690000 153000 88000 61000 58000
INRmax (Ratio) 0.8–1.25 2.11 3.24 1.34 1.47
Inﬂammatory markers
White blood cellmax (1000/l) 3.6–10.0 16.7 28.280 16.999 12.800 3.690
Normoblast absolute (1000/l) None 0 22.220 2.101 0 16.810
Procalcitoninmax (pg/ml) 0.1–0.5 5.61 13.67 85.78 2.9 420
sCD25 (U/ml)∗ <1000 2220 2160 3916
TNF-α (pg/ml)∗ <3 90.4 104.8 98.4
IL-8 (pg/ml)∗ <3 152 346 328
IL-6 (pg/ml)∗ <6 72 108 55.6
IL-1β (pg/ml)∗ <5 2.9 4.0 1.68
hs CRPmax (mg/dl) <1.0 0.00 0.21 0.83 0.21 0.00
NT-Pro-BNP (pg/ml) 0–85 6374 31127 31689 71485
Ferritin (μg/l)∗ 20–400 33016 27516 94099 419 3676
Triglyceride (mg/dl) 35–180 1349 222 327
Serum Calciummin (mmol/l) 2.15–2.75 1.81 2.23 1.61 2.54 2.05
∗: measurements from stored plasma
§: left ventricular pressure estimated from Doppler measurements of mitral valve regurgitant jet velocity
#: systolic pulmonary artery pressure estimated using Doppler measurements across pulmonary artery band:
Pulmonary artery pressuresys = LV pressure – PAB gradient.
performed for left-sided diaphragmatic paralysis. Supportive
pharmacotherapy consisted of digoxin, captopril, spirono-
lactone, and high-dose furosemide. In addition, a gastro-
duodenal tube (G-Tube) was placed for feeding because of
vomiting and poor oral intake. The hospital course was
complicated by more than 10 endotracheal intubations for
recurrent respiratory failure, which appeared to be triggered
by exacerbations of an inﬂammatory disease process of
unknown origin. During this time the infant underwent
multiple courses of antibiotic treatment. Despite multiple
diagnostic eﬀorts, the cause of the recurrent sepsis-like
exacerbations could not be determined.
The hemodynamic status was characterized by good
cardiac performance of the functionally single ventricle
despite persistent pulmonary hypertension (Table 1). There
was clear evidence for ongoing pulmonary vascular disease
with pulmonary hypertension and need for oxygen sup-
plementation. In this situation, stage 2 palliation (superior
cavopulmonary connection, bidirectional Glenn shunt) of
his single ventricle defect was considered contraindicated.
Since we hypothesized that the recurrent clinical symptoms
of heart failure were caused by neurohormonal and inﬂam-
matory dysfunction we started a trial of low-dose beta-
blocker therapy with 0.3mg/kg/day propranolol (0.1mg/kg
per dose) by G-Tube in accordance with the German
guidelines for congenital heart defects in children [2, 3].
During the next fever episode the infant developed
signs of hepatic failure and pulmonary edema and required
intubationwithmechanicalventilationaswellasintravenous
antibiotics and aggressive diuretic treatment. Since theCardiology Research and Practice 3
hemodynamic and cardiac function improved, propranolol
therapy was not stopped. He recovered from this initial
episode of systemic inﬂammatory response syndrome (SIRS)
(see SIRS I in Table 1 ) within 3 days. He was extubated with-
out dyspnea and began to tolerate oral feeding. However the
fever continued unabated and when we stopped antibiotic
coverage to collect blood cultures he decompensated with
signs of an exacerbation of the SIRS II (see Table 1).
Furthermore we switched the medication to the selective
β1-blocker metoprolol. The patient stabilized quickly again
but the fever continued. Since all blood cultures remained
negative, we hypothesized that the source of recurrent
endotoxemia may be gastrointestinal. One week later we
decided to remove as many potential sources of infection as
possible. We removed not only the central venous catheter
but also the G-Tube. Subsequent blood cultures and the
central venous catheter cultures were negative, but resistant
E.coliwasrecoveredfromthejejunalendofthefeedingtube.
Theinfantimprovedwithoraltreatmentwithcotrimoxazole.
His supplemental oxygen requirements ceased during his
oxygen saturation rose to 90% and the pulmonary arterial
pressure decreased to the normal range. After six months
of intensive care, including 12 intubations for respiratory
failure, he was discharged home. Two days later he was
readmitted for fever and decreasing oxygen saturations due
to bronchospasm. An etiology of the bronchospasm could
not be ascertained. Despite intensive therapy with systemic
and inhalational β2-adrenergic agonists, theophylline, and
high-doseprednisolone, thebronchospasmpersistedandthe
infant’sconditiondeteriorated.Metoprololwasdiscontinued
and mechanical ventilation was reinitiated. A subsequent
event of pulmonary hypertensive crisis ensued and unfortu-
nately the patient expired (SIRS III). Post mortem the results
of a bone marrow aspirate showed hemophagocytosis and
thediagnosisofHLHwasveriﬁedbyahighlyelevatedferritin
and soluble CD25 receptor levels. Especially the cytokine
proﬁles conﬁrmed the diagnosis of HLH. Epstein-Barr virus
infection could be excluded by polymerase chain reaction.
3. Discussion
HLH can mimic heart failure with signs of hepato-
splenomegaly, dystrophy, pulmonary, and systemic conges-
tion resistant to diuretic therapy. HLH in our patient was not
recognized earlier, because this entity has not been described
in the context of heart failure [4]. Immunoactivation due to
heart failure has been reported in adults with left ventricular
dysfunction [5] and in children with congenital heart disease
[6]. We have previously reported elevated cytokine levels
in infants with heart failure and the beneﬁcial eﬀect of
propranolol [7]. As shown in Table 1,i m m u n o a c t i v a t i o n
in our patient was characterized by high procalcitonin and
cytokine levels. This constellation together with normal
high sensitivity C-reactive protein values and highly elevated
probrain natriuretic peptide (NT-Pro-BNP) was indicator of
anSIRS[8]ofanon-infectiousetiology.Inthissituationlow-
dose propranolol led to an unexpected hepatic compromise
as indicated by high lactate dehydrogenase and alanine
aminotransferase levels unrelated to the deterioration of
global hemodynamics. Severe liver cell necrosis was also
described during β2-blockade in systemic inﬂammatory
response syndrome in animals [9].
The observed hyperinﬂammatory response with liver
cell necrosis appears to be β2-receptor mediated since we
did not observe similar elevations of lactate dehydrogenase
and alanine aminotransferase levels during therapy with the
selective β1-antagonist metoprolol. However, in whole blood
samples from patients with heart failure bisoprolol, another
β1-selective betablocker, but not metoprolol or carvedilol
augments LPS-stimulated TNF-α production [10]. These
results are rather curious and need further investigation. It
is also possible that the nonspeciﬁc β-blocker impaired NK
activation and thus promoted HLH [11].
It is becoming evident that sympathetic nervous system
activation may play a dual role during any inﬂammatory
response. While it clearly has profound anti-inﬂammatory
eﬀects during systemic inﬂammation, a recently published
study suggests that the local inﬂammatory response can
be immensely ampliﬁed by local cell-derived catecholamine
production. Thus, catecholamines enhance cytokine release
by macrophages via activation and translocation of NFκB,
demonstrating that catecholamines are powerful cellular
hormones that self-regulate the activation level and the
inﬂammatory potential of inﬂammatory cells [12]. Since
HLH is causally related to NK dysfunction and concurrent
viral infections in the majority of cases, the activation of NK
function demonstrated by β-receptor blockade in a surgical
and cancer model is noteworthy [13].
4. Conclusion
Our case describes an infant with secondary HLH due
to heart failure and Downs syndrome. In this highly
activated inﬂammatory state the beneﬁcial hemodynamic
eﬀects of propranolol may be accompanied by unexpected
immunomodulatory eﬀects and the risk of acute liver failure.
Before institution of β-blocker therapy in patients with
heart failure associated with inﬂammation, HLH has to
be excluded by clinical and laboratory ﬁndings focussing
on soluble CD25 [14] and ferritin measurement [15].
HLH occurs with a distinct pathophysiology, and speciﬁc
treatment is mandatory to increase the chance of survival
[16].
Appendix
A trial of beta-blocker therapy was initiated after receiving
full-informedconsentfromtheparents.Theethiccommittee
waived the need for approval.
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